Evidence map›Paper›PMID 28875984›Full record

ReviewNature nanotechnology2017

Multiscale technologies for treatment of ischemic cardiomyopathy.

Morteza Mahmoudi, Mikyung Yu, Vahid Serpooshan, Joseph C Wu, Robert Langer, Richard T Lee, Jeffrey M Karp, Omid C Farokhzad

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature nanotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. A BACH1 inhibitor ameliorates myocardial infarction and limb ischemia in mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  9. Image-Guided Cardiac Regeneration via a 3D Bioprinted Vascular Patch with Built-in CT Visibility.Chemical engineering journal (Lausanne, Switzerland : 1996) · 2025
    Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Morteza MahmoudiCenter for Nanomedicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Mikyung YuCenter for Nanomedicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Vahid SerpooshanStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California 94305, USA.
Joseph C WuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California 94305, USA.
Robert LangerThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Richard T LeeDepartment of Stem Cell and Regenerative Biology, Harvard University, Harvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA.
Jeffrey M KarpCenter for Nanomedicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Omid C FarokhzadCenter for Nanomedicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

Funding

Enhancing Inflammation Resolution in Atherosclerosis via Targeted Nanoparticle-Mediated Delivery of BiologicsR01HL127464 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHI, JINJUN, TABAS, IRA A · 2016 to 2019
$3.0M
Development of FcRn-Targeted Nanoparticles for Efficient Oral Delivery of InsulinR01EB015419 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI FAROKHZAD, OMID C, KARNIK, ROHIT N · 2012 to 2015
$2.8M
Molecular Imaging of Cardiac Pluripotent Stem CellsR01HL133272 · NHLBI · STANFORD UNIVERSITY · PI WU, JOSEPH C. · 2016 to 2020
$2.4M
NHLBI NIH HHS R01 HL127464NHLBI NIH HHS R01 HL133272NIBIB NIH HHS R01 EB015419
6 · The paper itself

Abstract

The adult mammalian heart possesses only limited capacity for innate regeneration and the response to severe injury is dominated by the formation of scar tissue. Current therapy to replace damaged cardiac tissue is limited to cardiac transplantation and thus many patients suffer progressive decay in the heart's pumping capacity to the point of heart failure. Nanostructured systems have the potential to revolutionize both preventive and therapeutic approaches for treating cardiovascular disease. Here, we outline recent advancements in nanotechnology that could be exploited to overcome the major obstacles in the prevention of and therapy for heart disease. We also discuss emerging trends in nanotechnology affecting the cardiovascular field that may offer new hope for patients suffering massive heart attacks.

Indexed as

AnimalsCardiomyopathiesCell- and Tissue-Based TherapyCoronary Artery DiseaseDrug Delivery SystemsHeartHumansMyocardial IschemiaNanomedicineNanostructuresNanotechnologyRegenerationTissue Scaffolds

Identifiers

PMID28875984
PMCPMC5717755

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.